Navigation Links
Keryx Biopharmaceuticals, Inc. Prices Common Stock Offering
Date:5/4/2011

y Street, Suite 3700, San Francisco, California 94104, or by phone at (415) 364-2720.

ABOUT KERYX BIOPHARMACEUTICALS, INC.

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of cancer and renal disease. Keryx is developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, and also affects a number of other key signal transduction pathways, including the JNK pathway, all of which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 has demonstrated both safety and clinical efficacy in several tumor types, both as a single agent and in combination with novel therapies. KRX-0401 is currently in Phase 3 clinical development for both refractory advanced colorectal cancer and multiple myeloma, and in Phase 1 and 2 clinical development for several other tumor types. Each of the KRX-0401 Phase 3 studies is being conducted under a Special Protocol Assessment (SPA) agreement with the Food and Drug Administration (FDA). Keryx is also developing Zerenex (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. The Phase 3 clinical program of Zerenex in the treatment for hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease is being conducted pursuant to an SPA agreement with the FDA. Keryx is headquartered in New York City.

KERYX CONTACT:
Lauren Fischer
Director - Investor Relations
Keryx Biopharmaceuticals, Inc.
Tel: 212.531.5965
E-mail: lfischer@keryx.com


'/>"/>
SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Keryx Biopharmaceuticals Announces Commencement of Phase 3 Program of Ferric Citrate (Zerenex™) in Japan by Partner, Japan Tobacco and Torii Pharmaceutical
2. Keryx Biopharmaceuticals Announces Two Poster Presentations on KRX-0401 (Perifosine) at Upcoming American Association for Cancer Research (AACR) Annual Meeting
3. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2010 Financial Results
4. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year End 2010 Financial Results on Wednesday, March 9, 2011 at 8:30 a.m. ET
5. Keryx Biopharmaceuticals Announces Oral Presentation of Final Zerenex™ Short-Term Phase 3 Data at the Upcoming National Kidney Foundations 2011 Spring Clinical Meetings
6. Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
7. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2010 Financial Results
8. Keryx Biopharmaceuticals Announces Completion of Patient Enrollment In Zerenex Phase 3 Short-Term Study
9. Keryx Biopharmaceuticals to Present at BioCenturys NewsMakers in the Biotech Industry Conference
10. Keryx Biopharmaceuticals to Present at JMP Securities Healthcare Conference
11. Keryx Biopharmaceuticals to Present at the 22nd Annual ROTH OC Growth Stock Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... , June 2, 2015  Endo International plc (NASDAQ: ... announced today that it has commenced an underwritten public ... All ordinary shares in the offering are to be ... also grant to the underwriters of the Offering an ... the date of the final prospectus supplement, to purchase ...
(Date:6/2/2015)...  MGC Diagnostics Corporation (NASDAQ: MGCD ), ... results for the second quarter ended April 30, ... equipment, supplies and accessories revenues, compared to the ... During the quarter, competitive account conversions totaled 12 ... accounts, or $850,000 in revenue for the same ...
(Date:6/2/2015)... 2, 2015   PDI , a leader ... a series of corporate commitments designed to educate ... the threat of antimicrobial-resistant microorganisms as part of ... Disease Control and Prevention (CDC) and in support ... Antibiotic-Resistant Bacteria. Along with other key ...
Breaking Medicine Technology:Endo International plc Announces Proposed Public Offering of $1.75 Billion of Ordinary Shares 2Endo International plc Announces Proposed Public Offering of $1.75 Billion of Ordinary Shares 3Endo International plc Announces Proposed Public Offering of $1.75 Billion of Ordinary Shares 4MGC Diagnostics Corporation Reports Fiscal 2015 Second Quarter Results 2MGC Diagnostics Corporation Reports Fiscal 2015 Second Quarter Results 3MGC Diagnostics Corporation Reports Fiscal 2015 Second Quarter Results 4MGC Diagnostics Corporation Reports Fiscal 2015 Second Quarter Results 5MGC Diagnostics Corporation Reports Fiscal 2015 Second Quarter Results 6MGC Diagnostics Corporation Reports Fiscal 2015 Second Quarter Results 7MGC Diagnostics Corporation Reports Fiscal 2015 Second Quarter Results 8MGC Diagnostics Corporation Reports Fiscal 2015 Second Quarter Results 9MGC Diagnostics Corporation Reports Fiscal 2015 Second Quarter Results 10MGC Diagnostics Corporation Reports Fiscal 2015 Second Quarter Results 11MGC Diagnostics Corporation Reports Fiscal 2015 Second Quarter Results 12MGC Diagnostics Corporation Reports Fiscal 2015 Second Quarter Results 13MGC Diagnostics Corporation Reports Fiscal 2015 Second Quarter Results 14PDI Partners with White House and Centers for Disease Control and Prevention (CDC) to Combat Antimicrobial Resistance 2
... TORONTO, Nov. 8, 2010 Millennium Research Group ... intelligence, has released its latest surgical navigation systems ... geographies. These two reports cover the breakdown of ... used in neurosurgery, spine, ENT, orthopedic, and soft ...
... SALT LAKE CITY, Nov. 8, 2010 TechniScan, Inc. ... device company engaged in the development and commercialization of an ... its convertible debt. TechniScan entered into amendments with ... extend the maturity date of its entire portfolio of secured ...
Cached Medicine Technology:Medtronic, Stryker, and BrainLAB Covered in New Surgical Navigation Market Research Reports Released by Millennium Research Group 2TechniScan, Inc. Announces Restructuring of Convertible Debt 2
(Date:6/3/2015)... evigilo, a world leader in delivering ... new branding by launching a new and enhanced content-centric ... identity: the logo depicting a sun-like image with a ... – To Know. To Act. In time. The color ... A global, borderless approach to alerting and delivering safety ...
(Date:6/2/2015)... Prairie, WI (PRWEB) June 03, 2015 ... for regulated industries such as government, finance and healthcare. ... organization that wants reliable access control to enhance the ... card keyboard requires the secondary authentication of a Smart ... In addition to the smart-chipset card reader, the keyboard ...
(Date:6/2/2015)... MEDIA ADVISORY, June 2, 2015 ... Email: ewallace(at)mentalhealthamerica(dot)net , Breaking News: Congressman Tim Murphy ... at MHA Annual Conference Thursday , Who: Congressman ... address the Mental Health America Annual Conference attendees ... of the Helping Families in Mental Health Crisis ...
(Date:6/2/2015)... Los Angeles, CA (PRWEB) June 02, 2015 ... clinic have unveiled a plan to drive prolific change in ... progress, the TDC Team Dental Clinic offers a ... and an expert management structure for dental tourism. , Partnered ... dental care team is committed to advancing dentistry and has ...
(Date:6/2/2015)... UCLA Health and Exer have completed negotiations and ... urgent care services in Los Angeles County. The ... California Board of Regents and the Exer Board of ... purchase a minority share of four existing Exer urgent ... Northridge and creates opportunity to grow and develop new, ...
Breaking Medicine News(10 mins):Health News:Keep calm! evigilos' "sun" will come out tomorrow – to know, to act, in time. 2Health News:Introducing the New CHERRY JK-A0100EU Keyboard with Integrated Smart Card Reader for Access Control Security 2Health News:Congressman Tim Murphy to Unveil Details of New Mental Health Legislation at MHA Annual Conference Thursday 2Health News:Team Dental Clinic Unveils Plan to Drive Change in the Dental Tourism Industry 2Health News:Team Dental Clinic Unveils Plan to Drive Change in the Dental Tourism Industry 3Health News:UCLA Health Partners With Exer - More Than Urgent Care 2
... to earn the dubious distinction of becoming a country with ... better emergency facilities for heart patients could save lives, feel ... reports, India is likely to become the heart attack capital ... been spreading like an epidemic and have been affecting the ...
... Onyx Pharmaceuticals, Inc. today announced that Nexavar(R) (sorafenib) ... with hepatocellular carcinoma (HCC), or primary liver cancer ... presented at the 43rd annual meeting of the ... ,The international, Phase 3, placebo-controlled Sorafenib HCC Assessment ...
... two new investigational cancer therapies at the American Society ... a small molecule inhibitor of Poly-ADP Ribose Polymerase (PARP). ... Excision Repair which is a key pathway in the ... mechanism, in tandem with a defective DNA repair gene ...
... 4, 2007 An international team led by MUHC has ... is a common congenital blindness in infants and small children. ... Nature Genetics and is partly funded by the Foundation Fighting ... potential to fast-track a cure for this disease, says lead ...
... The winds of change and a yearning for variety are ... vodka and gin even as the old generation still ... ,As part of the global trend, the consumption of ... up in the subcontinent, thanks to the changing profile of ...
... to a University of Pittsburgh Medical Center (UPMC) study ... of Clinical Oncology (ASCO) in Chicago and published as ... for follicular lymphoma, a slow-growing type of non-Hodgkins lymphoma, ... ,Over 90 percent of study patients responded completely to ...
Cached Medicine News:Health News:Nexavar Significantly Extends Survival of Liver Cancer Patients 2Health News:Astrazeneca's Investigational Cancer Therapies Revealed at ASCO 2Health News:Astrazeneca's Investigational Cancer Therapies Revealed at ASCO 3Health News:Gene Responsible for Blindness in Infants and Children Identified 2Health News:Young Indians Say Cheers to White Spirits 2Health News:Young Indians Say Cheers to White Spirits 3Health News:Lymphoma Patients Maybe Helped by Adding Radioimmunotherapy to Chemo 2
QIAvac 6S provides all manifold components for processing QIAGEN 8-well strips....
Holder for QIAGEN 96-well plates, for use with QIAvac 96;...
For processing mini spin columns on QIAvac 24;...
DNA/RNA preparation in 384-well format...
Medicine Products: